Friday 18 Jul, 2025 10:50 AM
Site map | Locate Us | Login
   Tata Comm climbs post Q1 results; board clears NCD issue, internal restructuring    Shoppers Stop net loss narrows to Rs 18 crore in Q1 FY26    Sunteck Realty gains after Q1 PAT jumps 47% YoY    Saregama strikes a high note with Haryanvi catalogue takeover    Veranda Learning Solutions launches QIP with floor price of Rs 236.92/share    Wipro gains as Q1 PAT jumps 11% YoY to Rs 3,330 cr; declares dividend of Rs 5/sh    Axis Bank drops after Q1 PAT tumbles 4% YoY to Rs 5,806 cr    Godrej Properties acquires land in North Bengaluru for residential plotted development project    Axis Bank Ltd Slips 5.13%, BSE BANKEX index Shed 1.06%    InfoBeans Technologies Ltd Spurts 6.5%    EMS bags Rs 19-cr order from Deltabulk Shipping India    Axis Bank Q1 PAT slides 4% YoY to Rs 5,806 cr    Wipro Q1 PAT drops 7% QoQ to Rs 3,330 cr; declares dividend of Rs 5/sh    Waaree Energies drops after scrapping Kamath Transformers deal    Heritage Foods slumps as Q1 PAT tanks 31% YoY to Rs 41 crore 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Glenmark Pharma receives warning letter from USFDA for Indore facility
14-Jul-25   10:08 Hrs IST

The USFDA inspection was conducted between 3 February and 14 February 2025.

In an official filing, the company stated that it does not anticipate the warning letter will disrupt supply chains or affect revenues generated from the Indore facility. Glenmark emphasized its commitment to addressing the FDA's concerns promptly and working closely with the regulator to resolve the issues.

The company further clarified that there were no observations related to data integrity during the inspection. Glenmark reaffirmed its dedication to maintaining the highest quality and compliance standards, including adherence to Current Good Manufacturing Practices (CGMP), across all its facilities.

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

On a consolidated basis, Glenmark Pharmaceuticals reported a net profit of Rs 4.65 crore in Q4 March 2025 as against a net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025.

The scrip shed 0.56% to Rs 2,169.30 on the BSE.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | Rights & Obligations-English | (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC | Policy On Inactive Trading Accounts | Risk Disclosure Hit Count : 42759240
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited